

CASE 33522-US-PCT

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10	
EV 678115055US	6/19/06
Express Mail Label Number	Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF

BAESCHLIN ET AL.

INTERNATIONAL APPLICATION NO: PCT/EP2004/013412

FILED: 25 NOVEMBER 2004

U.S. APPLICATION NO: 10/579,427

35 USC §371 DATE: 12 MAY 2006

FOR: ORGANIC COMPOUNDS

MS: Amendment

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is being filed within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 of the international application. Therefore, no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.


In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The listed references were cited in the international stage search report. Since these references are of record in the instant PCT application PCT/EP2004/013412, copies are not enclosed herewith. References AA to AE are US equivalents of EP 0 678 503 A.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-7831



Gregory D. Ferraro
Attorney for Applicants
Reg. No. 36,134

Date:

6/19/06

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
33522-US-PCT
APPLICATION NO.
10/579,427
APPLICANT
BAESCHLIN ET AL.
FILING DATE
MAY 12, 2006

Group

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	5,559,111	9/24/96	Göschke et al.	514	227	4/4/95
	AB	5,606,078	2/25/97	Göschke et al.	549	321	4/4/95
	AC	5,627,182	5/6/97	Göschke et al.	514	237	7/25/96
	AD	5,646,143	7/8/97	Göschke et al.	514	233	7/25/96
	AE	5,705,658	1/6/98	Göschke et al.	549	321	2/14/97
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM	WO 02/40007 A	5/23/02	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AN	WO 03/103653 A	12/18/03	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AO						<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	Wood et al, Biochemical and Biophysical Research Communications 308, pp. 698-705, "Structure-based design of aliskiren, a novel orally effective rennin inhibitor. (2003)
	AS	Goeschke et al. Bioorganic & Medicinal Chemistry Letters, Vol. 7, No. 21, pp 2735-2740, Design and Synthesis of Novel 2,7-Dialkyl, Substituted 5(S)-Amino-4(S)-Hydroxy-8-Phenyl-Octanecarboxamides as <i>in Vitro</i> Potent Peptidomimetic inhibitors of Human Renin
	AT	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.